Empowering Women's Health: Cosette Pharmaceuticals Acquires Vyleesi® and Expands Treatment Options for HSDD

As part of its commitment to improving women's health, Cosette Pharmaceuticals, Inc. has recently completed the acquisition of Vyleesi® from Palatin Technologies, Inc. This strategic move aims to increase access to treatment for Hypoactive Sexual Desire Disorder (HSDD), a common condition affecting millions of women in the United States.

HSDD is a recognized medical condition characterized by a persistent or recurrent absence of sexual fantasies and desire for sexual activity, which can cause significant personal distress and interpersonal difficulties. Despite being a well-known condition for over four decades, HSDD remains underdiagnosed and undertreated.

"This acquisition highlights Cosette's continued focus on improving women's health and our dedication to increasing awareness and education," stated Apurva Saraf, President and CEO of Cosette Pharmaceuticals. "Our partnership with the women's health community, combined with our strong commercial capabilities, will enhance access to Vyleesi® for the millions of women who suffer from HSDD."

The acquisition includes 5 Orange Book listed patents with protection extending until 2041, ensuring the continued availability of Vyleesi® to patients and healthcare professionals during the transition period. Vyleesi® is a novel and effective treatment option for HSDD that can be self-administered as needed in anticipation of sexual activity, providing women with greater control over their sexual desire.

Dr. Rachel Rubin, a Urologist and Sexual Medicine Specialist, emphasizes the importance of addressing HSDD and utilizing available treatment options. "Vyleesi® is a welcome tool in our biopsychosocial toolbox. Women with HSDD should not ignore or justify their symptoms and should talk to their healthcare provider about reclaiming their sexual desire."

Cosette Pharmaceuticals is dedicated to collaborating with healthcare professionals to ensure women with HSDD have access to Vyleesi®. The company offers a telemedicine option, allowing patients to connect with physicians conveniently. To learn more about HSDD and Vyleesi®, including Important Safety Information, visit www.vyleesi.com.

About Cosette Pharmaceuticals:

Cosette Pharmaceuticals, Inc. is a US-based pharmaceutical company specializing in women's health, cardiology, and dermatology. With a fast-growing portfolio of branded pharmaceuticals, Cosette is committed to quality manufacturing and innovation. Supported by 300+ dedicated employees, the company has corporate and manufacturing facilities in New Jersey and North Carolina. Cosette Pharmaceuticals is backed by Avista Capital Partners, a leading healthcare-focused private equity firm.

For more information about Cosette Pharmaceuticals and its products, visit www.cosettepharma.com. Stay updated by following them on LinkedIn.

In conclusion, Cosette Pharmaceuticals' acquisition of Vyleesi® marks a significant step forward in addressing HSDD and empowering women's health. By expanding treatment options and increasing accessibility, Cosette aims to make a positive impact on the lives of millions of women affected by this common yet often overlooked condition.